Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.

Autor: Morgan RD; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom., Clamp AR; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom., White DJ; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Price M; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom., Burghel GJ; North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Ryder WDJ; Manchester Clinical Trials Unit, University of Manchester, Manchester, United Kingdom., Mahmood RD; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Murphy AD; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Hasan J; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Mitchell CL; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Salih Z; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Wheeler C; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Buckley E; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Truelove J; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom., King G; Manchester Clinical Trials Unit, University of Manchester, Manchester, United Kingdom., Ainaoui Y; Manchester Clinical Trials Unit, University of Manchester, Manchester, United Kingdom., Bhaskar SS; North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Shaw J; Department of Histopathology, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Evans DGR; North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom.; Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom., Kilerci B; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Pearce SP; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Brady G; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Dive C; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., O'Connor JPB; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.; Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom., Wallace AJ; North West Genomic Laboratory Hub, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Rothwell DG; Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, United Kingdom., Edmondson RJ; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.; Department of Gynaecological Surgery, Manchester University NHS Foundation Trust, Manchester, United Kingdom., Jayson GC; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Jul 14; Vol. 29 (14), pp. 2602-2611.

Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer.

Autor: Xiao, Fen^1,2 (AUTHOR), Wang, ZhiBin² (AUTHOR), Qiao, Liu^1,2 (AUTHOR), Zhang, Xiu² (AUTHOR), Wu, NaYiYuan² (AUTHOR) wunayiyuan@163.com, Wang, Jing² (AUTHOR) wangjing0081@hnca.org.cn, Yu, Xing^1,3,4,5 (AUTHOR) xingyu@hunnu.edu.cn

Publikováno v: Journal of Translational Medicine. 8/21/2024, Vol. 22 Issue 1, p1-17. 17p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.